Perspectives on Hyperthermic Intraperitoneal Chemotherapy for Advanced Ovarian Cancer-Reply

Affiliations

¹ Center for Gynecologic Cancer, National Cancer Center, Goyang, South Korea.
² Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, South Korea.

Comment

Myong Cheol Lim et al. JAMA Surg. 2022.

. 2022 Oct 1;157(10):970-971.

doi: 10.1001/jamasurg.2022.2941.

¹ Center for Gynecologic Cancer, National Cancer Center, Goyang, South Korea.
² Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, South Korea.

No abstract available

Comment on

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY; HIPEC for Ovarian Cancer Collaborators. Lim MC, et al. JAMA Surg. 2022 May 1;157(5):374-383. doi: 10.1001/jamasurg.2022.0143. JAMA Surg. 2022. PMID: 35262624 Free PMC article. Clinical Trial.
Perspectives on Hyperthermic Intraperitoneal Chemotherapy for Advanced Ovarian Cancer.
Jastrzebski T. Jastrzebski T. JAMA Surg. 2022 Oct 1;157(10):970. doi: 10.1001/jamasurg.2022.2940. JAMA Surg. 2022. PMID: 35895050 No abstract available.
Perspectives on Hyperthermic Intraperitoneal Chemotherapy for Advanced Ovarian Cancer.
Bhatt A, Bhandoria G, Glehen O. Bhatt A, et al. JAMA Surg. 2022 Oct 1;157(10):969-970. doi: 10.1001/jamasurg.2022.2939. JAMA Surg. 2022. PMID: 35895071 No abstract available.